Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.

Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM.

Ann Fam Med. 2014 Mar-Apr;12(2):121-7. doi: 10.1370/afm.1601.

2.

Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.

Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA.

Clin Infect Dis. 2015 Feb 15;60(4):566-77. doi: 10.1093/cid/ciu914.

PMID:
25409476
3.

Azithromycin and the risk of cardiovascular death.

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM.

N Engl J Med. 2012 May 17;366(20):1881-90. doi: 10.1056/NEJMoa1003833.

4.

Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL.

Expert Opin Drug Saf. 2015 Feb;14(2):295-303. doi: 10.1517/14740338.2015.989210. Review.

5.

Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.

LaPlante KL, Mersfelder TL, Ward KE, Quilliam BJ.

Pharmacotherapy. 2008 Jan;28(1):82-9.

PMID:
18154478
6.

Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.

Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, Garg AX.

CMAJ. 2016 Apr 19;188(7):E120-9. doi: 10.1503/cmaj.150901.

7.

Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.

Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, Restrepo MI, Downs JR, Anzueto A.

JAMA. 2014 Jun 4;311(21):2199-208. doi: 10.1001/jama.2014.4304.

8.

Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Lane MA, Zeringue A, McDonald JR.

Am J Med. 2014 Jul;127(7):657-663.e2. doi: 10.1016/j.amjmed.2014.01.044.

9.

Azithromycin and the risk of cardiovascular complications.

Maisch NM, Kochupurackal JG, Sin J.

J Pharm Pract. 2014 Oct;27(5):496-500. Review.

PMID:
25374989
10.

Use of azithromycin and death from cardiovascular causes.

Svanström H, Pasternak B, Hviid A.

N Engl J Med. 2013 May 2;368(18):1704-12. doi: 10.1056/NEJMoa1300799.

11.

Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.

Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, Tennenberg AM.

Eur Respir J. 2005 Jun;25(6):1001-10.

12.

Oral erythromycin and the risk of sudden death from cardiac causes.

Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM.

N Engl J Med. 2004 Sep 9;351(11):1089-96.

13.

Fatal heart rhythms associated with azithromycin.

Khan MS, Bawany FI, Hussham M.

J Pak Med Assoc. 2014 Feb;64(2):238. No abstract available.

14.

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial.

Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD.

Ann Intern Med. 1996 May 1;124(9):785-91.

PMID:
8610947
15.

Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico.

Adachi JA, Ericsson CD, Jiang ZD, DuPont MW, Martinez-Sandoval F, Knirsch C, DuPont HL.

Clin Infect Dis. 2003 Nov 1;37(9):1165-71.

PMID:
14557959
16.

Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients.

Wang PS, Levin R, Zhao SZ, Avorn J.

J Am Geriatr Soc. 2002 Jan;50(1):117-24.

PMID:
12028256
17.

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.

Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023.

PMID:
18343274
18.

Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG.

Scand J Gastroenterol. 2013 Jun;48(6):652-6. doi: 10.3109/00365521.2013.786132.

PMID:
23556551
19.

Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center.

Lee RA, Guyton A, Kunz D, Cutter GR, Hoesley CJ.

J Hosp Med. 2016 Jan;11(1):15-20. doi: 10.1002/jhm.2448.

PMID:
26287278
20.

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.

Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.

Curr Med Res Opin. 2009 Apr;25(4):859-68. doi: 10.1185/03007990902779749 .

PMID:
19231913
Items per page

Supplemental Content

Support Center